



HIV drug resistance & Phylogeny

By: K. Baesi



Natural selection

- High turnover
- Mutation: 1 error/70 nt
- Recombination
- Viral reservoir





Drug resistance

- HIV drug resistance refers to the ability of HIV to replicate in the presence of drugs
- Factors contributing to the selection of HIV drug resistance:
 - Regimen and drug-specific
 - Virus-related factors
 - Patient-specific factors
 - Programmatic factors



NRTIs


- 1- Sterical-inhibition: K65R, L74V, Q151M, M184V
- 2- Pyrophosphorylysis: M41L, D67N, K70R





NNRTIs


L100I, K103N, Y181C





PIs

- Early & secondary mutations: M46I ‘I50V ‘ V82A ‘L90M





Why is drug resistance important?

- Drug resistance is the major obstacle for effective treatment (ADR & TDR)
- Monitoring HIV drug resistance is critical for optimal program management:
 - **Transmitted drug resistance (TDR)**
 - Selecting first-line treatment regimens
 - Identifying the most effective second-line
 - Selecting optimal approaches for preventing mother-to-child transmission



Drug resistance

- Minimizing drug resistance to HAART is important
- Entry into care
- ART initiation or switch
- Treatment failure
- In patients HIV RNA levels >1000 copies/mL
- Women entering pregnancy with detectable HIV RNA levels while on therapy
- within 4 weeks after discontinuing therapy



Mutation – treatment correlation

➤ AZT

- TAMs (M41L, D67N/E/G, L210W, T215F/Y K219E/Q/N/R)
- T69I

- M184V

➤ 3TC

- M184V
- TAMs (M41L, D67N/E/G, L210W, T215F/Y K219E/Q/N/R)



Drug resistance in Iran

| Researcher | Journal | Year | NRTIs | NNRTIs | PIs |
|--------------------|-------------------------------------|------|-------|--------|------|
| Hamkar, et al | AIDS | 2010 | 76% | 74% | 45% |
| Mousavi, et al | Archives of virology | 2010 | 2.5% | | 2.5% |
| Baesı, et al | Iranian journal of biotechnology | 2012 | 66% | 32% | |
| Baesı, et al | Modares Journal of Medical Sciences | 2012 | | | 40% |
| Jahanbakhsh, et al | Plos one | 2013 | 4.3% | | |
| Baesı, et al | Journal of medical virology | 2014 | 51% | 61% | 40% |
| Memarnejadian | Plos one | 2015 | 10% | 5% | |




HIV Phylogeny

- **HIV-1 Major (M):** A-D, F-H, J and K (90%)
- **CRFs:** 72 CRFs (AE, AG, BC, ...)
- **URFs:** more than 1000 URF
- **HIV-1 Outlier (O)**
- **HIV-1 Not M_Not O(N)**
- **HIV-1 P group**
- **HIV-2**
- **SIV**




HIV-1 phylogeny





HIV phylogeny in Iran



IRAN, ISLAMIC REPUBLIC OF

| | | |
|-------|-----|---------|
| 01_AE | 15 | 1.5 % |
| 35_AD | 764 | 77.2 % |
| A | 47 | 4.8 % |
| B | 141 | 14.3 % |
| C | 21 | 2.1 % |
| other | 1 | 0.1 % |
| total | 989 | 100.0 % |

سال ها ره می رویم و در اخیر
هم چنان در منزل اول اسیر

Thanks



علم کوه دمچه لشگری